PLUS THERAPEUTICS Revenue and Competitors
Estimated Revenue & Valuation
- PLUS THERAPEUTICS's estimated annual revenue is currently $2.4M per year.
- PLUS THERAPEUTICS's estimated revenue per employee is $100,500
Employee Data
- PLUS THERAPEUTICS has 24 Employees.
- PLUS THERAPEUTICS grew their employee count by 14% last year.
PLUS THERAPEUTICS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $16.1M | 80 | -2% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $10.1M | 50 | 6% | N/A | N/A |
#6 | $119.4M | 594 | 27% | N/A | N/A |
#7 | $22.9M | 114 | 8% | N/A | N/A |
#8 | $92.9M | 462 | 8% | N/A | N/A |
#9 | $11.3M | 56 | -8% | N/A | N/A |
#10 | $7M | 35 | 6% | N/A | N/A |
What Is PLUS THERAPEUTICS?
PLUS THERAPEUTICS (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our lead drug candidate, Rhenium-186 Nanoliposome, is being evaluated in the NIH-supported multi-center ReSPECT clinical trials for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
keywords:N/A
N/A
Total Funding
24
Number of Employees
$2.4M
Revenue (est)
14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 24 | -33% | N/A |
#2 | $5.4M | 24 | 14% | N/A |
#3 | $2.9M | 24 | -64% | $254M |
#4 | $1.7M | 24 | -37% | $4.8M |
#5 | $2.4M | 24 | N/A | N/A |